ArticleCardiovascular diabetology2015
Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk.
Article in Cardiovascular diabetology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC medicine · 2024Pooled it
- Waistline to thigh circumference ratio as a predictor of MAFLD: a health care worker study with 2-year follow-up.BMC gastroenterology · 2024Article
- Effect of Adult Weight Gain on Non-Alcoholic Fatty Liver Disease and Its Association with Anthropometric Parameters in the Lean Japanese Population.Diagnostics (Basel, Switzerland) · 2020Article
- Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis.Hepatology communications · 2020Article
- Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population.International journal of environmental research and public health · 2020Article
- The methylenetetrahydrofolate reductase genotype 677CT and non-alcoholic fatty liver disease have a synergistic effect on the increasing homocysteine levels in subjects from Chongqing, China.Genes & diseases · 2019Article
- Dysregulation of the Mitochondrial Proteome Occurs in Mice Lacking Adiponectin Receptor 1.Frontiers in endocrinology · 2019Article
- Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease.Lipids in health and disease · 2017Article
- Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects.Medicine · 2017Observational
- Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia.Medicine · 2017Observational
- The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease.Lipids in health and disease · 2017Article
- Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.Cardiovascular diabetology · 2016Article
- The nine-year changes of the incidence and characteristics of metabolic syndrome in China: longitudinal comparisons of the two cross-sectional surveys in a newly formed urban community.Cardiovascular diabetology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to determine the association between nonalcoholic fatty liver disease (NAFLD) and diabetes risk among body size phenotypes which was based on cross-classification of body mass index (BMI) categories (normal or overweight/obesity) and metabolic status (metabolically health or metabolically at-risk).
methodsWe conducted a cross-sectional analysis using a cohort of 10,761 apparently healthy Chinese adults who underwent comprehensive health checkups including abdominal ultrasonography. Subjects were classified as metabolically at-risk by having any two of the following, consistent with the Adult Treatment Panel-III metabolic syndrome definition: (1) systolic/diastolic blood pressure ≥130/85 mmHg, (2) triglycerides ≥1.7 mmol/L, (3) fasting blood glucose ≥5.6 mmol/L, (4) HDL-cholesterol ≥1.0/1.3 mmol/L for men/women.
resultsAmong participants without metabolically at-risk, multivariate-adjusted odds ratios (ORs) for diabetes from NAFLD compared with those without NAFLD in the normal-weight (BMI <23 kg/m(2)) and overweight/obese (BMI ≥23 kg/m(2)) group were 2.10 (1.85-3.93) and 1.85 (1.35-2.53), respectively. Among participants with metabolically at-risk, the significant association between NAFLD and diabetes was lost, regardless of obesity status. There were only 27.1% subjects with the presence of the three factors (overweight/obesity, NAFLD, and metabolically at-risk) occurring together, while the three factors occurring together was common (56.16%) in diabetic individuals. The multivariate-adjusted ORs for diabetes were 1.1 (0.61-1.98) for overweight/obesity, 2.23 (1.05-5.14) for NAFLD, and 8.04 (5.0-12.09) for metabolically at-risk. The OR for the presence of all the three factors occurring together was 23.22 (13.96-38.63).
conclusionsNAFLD was associated with diabetes risk among participants without metabolically at-risk. The clustering of overweight/obesity, NAFLD, and metabolically at-risk is common in diabetic subjects and strikingly and markedly increases the diabetes risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.